Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RB515
- Development stage
- Preclinical
- Lead developer
- Allergan
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
RB515 is an oligonucleotide aptamer-based active control agent that is part of Regado Biosciences’ REG3 antithrombotic/antiplatelet program, which consists of a specific glycoprotein VI (GPVI) inhibitor aptamer (RB571) paired with its complementary control agent (RB515) to allow titratable, reversible modulation of GPVI-mediated platelet activation. Developed as a matched oligonucleotide designed to bind and neutralize the GPVI inhibitor aptamer, RB515 enables rapid and precise reversal of antiplatelet activity to improve the safety profile of REG3 in settings where on-demand control of platelet inhibition is required.
- Other names
- RB515 aptamer active controlRB-515 aptamer active controlRB 515 aptamer active controlREG3 active control oligonucleotideREG-3 active control oligonucleotideREG 3 active control oligonucleotide
Beyond the preview
Go deeper on RB515.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RB515.